Data Year:

For its 2025 fiscal year, ARVINAS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
John Houston Ph.D.
Former President and Chief Executive Officer
Total Compensation $6,534,127 View details Pay Rank By Title In Biotechnology industry #195 View more
Ian Taylor Ph.D.
Former President of Research and Development
Total Compensation $903,389 View details Pay Rank By Title In Biotechnology industry #59 View more
Noah Berkowitz M.D., Ph.D.
Chief Medical Officer
Total Compensation $3,593,956 View details Pay Rank By Title In Biotechnology industry #60 View more
Andrew Saik
Chief Financial Officer and Treasurer
Total Compensation $3,362,314 View details Pay Rank By Title In Biotechnology industry #118 View more
Angela Cacace Ph.D.
Chief Scientific Officer
Total Compensation $3,300,914 View details Pay Rank By Title In Biotechnology industry #18 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ARVINAS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ARVINAS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ARVINAS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John Houston Ph.D.
Former President and Chief Executive Officer
Total Cash $1,163,236 Equity $5,356,891 Other $14,000 $6,534,127
Ian Taylor Ph.D.
Former President of Research and Development
Total Cash $152,567 Equity $726,806 Other $24,016 $903,389
Noah Berkowitz M.D., Ph.D.
Chief Medical Officer
Total Cash $820,887 Equity $2,759,069 Other $14,000 $3,593,956
Andrew Saik
Chief Financial Officer and Treasurer
Total Cash $805,563 Equity $2,542,751 Other $14,000 $3,362,314
Angela Cacace Ph.D.
Chief Scientific Officer
Total Cash $744,163 Equity $2,542,751 Other $14,000 $3,300,914
For its 2025 fiscal year, ARVINAS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John Houston Ph.D. CEO Pay $6,534,127 Median Employee Pay $327,724 CEO Pay Ratio 20:1
For its 2024 fiscal year, ARVINAS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Briggs Morrison, M.D. Total Cash $480,385
Edward Kennedy, Jr. Total Cash $451,525
Everett Cunningham Total Cash $453,565
John Houston Total Cash $451,065
John Young Total Cash $451,065
Laurie Smaldone-Alsup, M.D. Total Cash $456,525
Leslie V. Norwalk, Esq. Total Cash $451,525
Linda Bain Total Cash $461,525
Sunil Agarwal, M.D. Total Cash $463,118
Wendy Dixon, Ph.D. Total Cash $31,277
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.